Rituximab and omalizumab in severe, refractory insulin allergy. (Record no. 18705161)

MARC details
000 -LEADER
fixed length control field 01562 a2200457 4500
005 - DATE AND TIME OF LATEST TRANSACTION
control field 20250515162154.0
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION
fixed length control field 200903s 0 0 eng d
022 ## - INTERNATIONAL STANDARD SERIAL NUMBER
International Standard Serial Number 1533-4406
024 7# - OTHER STANDARD IDENTIFIER
Standard number or code 10.1056/NEJMc0808282
Source of number or code doi
040 ## - CATALOGING SOURCE
Original cataloging agency NLM
Language of cataloging eng
Transcribing agency NLM
100 1# - MAIN ENTRY--PERSONAL NAME
Personal name Yong, Patrick F K
264 #0 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE
Date of production, publication, distribution, manufacture, or copyright notice 20090311
245 00 - TITLE STATEMENT
Title Rituximab and omalizumab in severe, refractory insulin allergy.
Medium [electronic resource]
260 ## - PUBLICATION, DISTRIBUTION, ETC.
Name of publisher, distributor, etc. The New England journal of medicine
Date of publication, distribution, etc. Mar 2009
300 ## - PHYSICAL DESCRIPTION
Extent 1045-7 p.
Other physical details digital
500 ## - GENERAL NOTE
General note Publication Type: Letter
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Anti-Allergic Agents
General subdivision therapeutic use
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Antibodies, Anti-Idiotypic
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Antibodies, Monoclonal
General subdivision therapeutic use
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Antibodies, Monoclonal, Humanized
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Antibodies, Monoclonal, Murine-Derived
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Diabetes Mellitus, Type 1
General subdivision drug therapy
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Drug Eruptions
General subdivision drug therapy
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Drug Therapy, Combination
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Female
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Humans
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Immunoglobulin E
General subdivision blood
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Immunologic Factors
General subdivision therapeutic use
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Insulin
General subdivision adverse effects
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Middle Aged
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Omalizumab
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Rituximab
700 1# - ADDED ENTRY--PERSONAL NAME
Personal name Malik, Rifat
700 1# - ADDED ENTRY--PERSONAL NAME
Personal name Arif, Sefina
700 1# - ADDED ENTRY--PERSONAL NAME
Personal name Peakman, Mark
700 1# - ADDED ENTRY--PERSONAL NAME
Personal name Amiel, Stephanie
700 1# - ADDED ENTRY--PERSONAL NAME
Personal name Ibrahim, Mohammad A A
700 1# - ADDED ENTRY--PERSONAL NAME
Personal name Gough, Andrew
773 0# - HOST ITEM ENTRY
Title The New England journal of medicine
Related parts vol. 360
-- no. 10
-- p. 1045-7
856 40 - ELECTRONIC LOCATION AND ACCESS
Uniform Resource Identifier <a href="https://doi.org/10.1056/NEJMc0808282">https://doi.org/10.1056/NEJMc0808282</a>
Public note Available from publisher's website

No items available.